Mounjaro weight loss injection results: what the trial data actually shows

The SURMOUNT-1 data: a closer look at the numbers behind the headline

SURMOUNT-1 randomised 2,539 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related condition) who did not have type 2 diabetes. Participants received once-weekly tirzepatide at 5mg, 10mg or 15mg, or a placebo, alongside a reduced-calorie diet and increased activity, the same combination a prescriber would expect alongside treatment today.

At 72 weeks, the average body-weight reductions were approximately 15% at 5mg, 19.5% at 10mg, and 20–21% at 15mg. Some analyses of the 15mg arm reported reductions approaching 22.5% in certain subgroups. The placebo group lost around 3%. That gap is large enough to be clinically meaningful, which is part of why NICE recommended tirzepatide in December 2024 for adults meeting specific BMI and comorbidity thresholds.

A dose-response pattern is visible in those figures. The 15mg maintenance dose produces the greatest average loss, but titration starts at 2.5mg, the opening pen exists to let your body adjust before the prescriber moves the dose upward, typically in four-week steps. More isn't always better immediately; how quickly someone tolerates each increase shapes the eventual therapeutic dose.

It is also worth remembering that these are averages across thousands of participants. Some people lose considerably more; others lose less. The trial was also conducted alongside structured lifestyle support, so the injection alone is not the whole picture.

What the head-to-head evidence adds

SURMOUNT-5, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg (the standard Wegovy maintenance dose) over 72 weeks in 751 adults with obesity and no diabetes. Tirzepatide produced greater average weight reduction. This is the strongest available evidence for positioning Mounjaro relative to other weight-loss injections, because it is a direct comparison rather than an indirect one across separate trials.

NICE's appraisal noted that indirect comparisons of trial data also tended to favour tirzepatide over semaglutide 2.4mg, and the committee factored this into its recommendation for TA1026.

The gap narrows with semaglutide 7.2mg, the higher dose approved by the MHRA in early 2026, which reported around 20.7% average weight loss over 72 weeks. So the landscape is still moving. For most patients starting a weight-loss injection now, the conversation about which medicine suits their situation is a clinical one, not just a comparison of headline percentages. Our prescribers at the nume clinical team (sorry, at the nume clinical team) work through exactly that with each patient.

Explore the detailed breakdown of Mounjaro injection results by dose if you want the figure-by-figure picture before your consultation.

Factors that influence how much weight someone loses on Mounjaro

Trial averages describe populations, not individuals. Several factors shape how results land for a specific person using Mounjaro weight-loss injections in practice.

Dose reached matters substantially. Someone who tolerates only 5mg (because higher doses cause persistent nausea, for instance) will sit closer to the 15% average than the 20% one. That is not a treatment failure; it is the medicine working at the right level for that person's physiology.

Lifestyle alongside treatment makes a measurable difference. The SURMOUNT-1 participants were following a reduced-calorie diet and activity programme. Weight loss on the injection alone, without any dietary change, would likely be lower. The injection reduces appetite noticeably for most people, which makes dietary adjustment easier, but it does not override eating habits entirely.

Injection technique and consistency are also relevant. Tirzepatide is given once weekly into the abdomen, thigh or upper arm, rotating sites each time. Keeping to the same day each week (some people slot it in before the kettle goes on, others after the gym) supports consistent drug levels. Detailed technique guidance is in our page on where to inject Mounjaro.

Finally, individual biology differs. How quickly someone's appetite responds, how they metabolise the medicine, and whether they have conditions that affect weight regulation all contribute. That variability is why the prescriber reviews every repeat order rather than treating the treatment as a set-and-forget prescription.

How results are monitored, and what happens if they plateau

Mounjaro is a Black Triangle medicine (▼), meaning the MHRA maintains additional monitoring. For practical purposes, this means the evidence base continues to grow and prescribers follow emerging safety communications alongside the established data.

On the clinical side, NICE guidance recommends reviewing whether treatment should continue if less than 5% of starting weight has been lost after six months at the highest tolerated dose. This is not a punitive threshold; it is a recognition that the medicine works well for most people and that continued prescription without effect is not in a patient's interest.

At Mounjaro reviews through nume, a prescriber personally checks progress before every repeat. There are no automatic renewals. If results have stalled or side effects have become problematic, that conversation happens in the clinical review, not in a call centre. You can read about what is included in the treatment cost, the review at every repeat is part of it, not an extra.

If you are deciding whether to start, the free consultation is where eligibility is assessed and the right medicine is matched to your situation.